At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 20 enrolled
Drug / intervention
oral estradiol 1.0 mg +1 moredrug
Likely dose
oral estradiol 1.0 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effect of Oral Estradiol and Progesterone Therapy on Vaginal Cytokines in Postmenopausal Women
In Brief
A Phase 3 clinical trial evaluating oral estradiol 1.0 mg and oral progesterone 100 mg for Menopause. Completed, enrolled 20 participants across 1 site.
Detailed Summary
The purpose of this study is to compare the vaginal health between premenopausal and postmenopausal women before and after using oral "estradiol" for 14 days then "estradiol" and "progesterone" for 14 days.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMenopause
CountriesUnited States
CollaboratorsTherapeuticsMD
Timeline
Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
First PostedAug 2014
Enrollment StartDec 2015
Primary CompletionAug 2018
TodayJul 2026
First PostedAug 25, 2014
Enrollment StartDec 1, 2015
Primary CompletionAug 1, 2018
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 11.9 years ago
Interventions
oral estradiol 1.0 mgdrug
one tablet of oral estradiol 1.0 mg once a day for 28 days
oral progesterone 100 mgdrug
one tablet of oral progesterone 100 mg once a day for 14 days